AGIO

Business Context and Reporting Period

Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 3, 2025
Subject: FDA approval of an update to the U.S. Prescribing Information (USPI) for PYRUKYND (mitapivat).

Key Financial Metrics

This filing is a regulatory update regarding product labeling and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

The material change reported is the FDA-approved update to the USPI for PYRUKYND, specifically affecting the "Warnings and Precautions" and "Adverse Reactions" sections:

• New Warning: Liver injury has been observed in patients with a condition other than pyruvate kinase (PK) deficiency who were treated with PYRUKYND at doses higher than recommended for PK deficiency.
• Event Characteristics: Onset occurred within the first 6 months of treatment. Peak elevations of alanine aminotransferase (ALT) were greater than 5 times the upper limit of normal (ULN), with or without jaundice.
• Outcome: All affected patients discontinued treatment, and events improved upon discontinuation.

Guidance, Outlook, and Management Commentary

Updated Prescribing Instructions:

• Obtain liver tests prior to initiation and monthly for the first 6 months.
• Interrupt PYRUKYND if clinically significant increases in liver tests are observed or if ALT is >5 times the ULN.
• Discontinue PYRUKYND if hepatic injury due to the drug is suspected.

Management Commentary: The filing contains no forward-looking guidance, outlook, or general management commentary beyond the regulatory update. No risks, contingencies, or unusual items outside of the specific liver injury warning were disclosed.

Investor Verification Checklist

• Verify the specific patient population (non-PK deficiency) associated with the reported liver injury events.
• Confirm the impact of the new monitoring requirements (monthly liver tests for 6 months) on clinical trial protocols or commercial prescribing practices.
• Review historical data to determine if similar liver injury events have occurred in the PK deficiency population at standard doses.
• Assess potential liability or reputational risk associated with the "Warnings and Precautions" update.